trial

Transcranial Magnetic Stimulation (TMS) in Schizophrenia

NCTId NCT00564096
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 20 (estimated)
Sponsored by BeerYaakov Mental Health Center
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-10
Primary completion
2011-11
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
DEEP TMS H1 coilDeep H1 coil TMS

Sponsors

BeerYaakov Mental Health CenterLead Sponsor
Weizmann Institute of ScienceCollaborator

Investigators

1
Oded Rosenberg, M.D.Principal Investigator

Sites

1 total
Beer Yaacov, Israel

Linked catalysts

1
Transcranial Magnetic Stimulation (TMS) in Schizophrenia — primary completion2011-11

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2,PHASE3
Primary Completion Date
2011-11
Status
UNKNOWN
relationships
The graph out of here
drug
DEEP TMS H1 coil
drug
Deep H1 coil TMS
drug
lead_sponsor
BeerYaakov Mental Health Center
company
collaborator
Weizmann Institute of Science
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Oded Rosenberg, M.D.
person